TD Cowen lowered the firm’s price target on Biogen (BIIB) to $275 from $300 and keeps a Buy rating on the shares. The firm said they reported Q3 revenue in line and EPS beat. 2024 EPS guidance was raised. Leqembi s launch continues to gain momentum but logistics and capacity constraints remain barriers to adoption.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB: